Mylan and federal investigators Thursday finalized a $465 million settlement of charges the drugmaker overcharged the government for the injection allergy medication EpiPen. Resolving an issue that ...

The publication spoke with 10 former Mylan executives who said they were not surprised the price is still so high. The unnamed executives said the drugmaker “has thrived by learning to absorb, and ...

Mylan’s $465 million proposed settlement with CMS may not cover the amount of money it allegedly saved by improperly classifying EpiPens as a generic drug, according to research published Monday in ...

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, ...

Mylan’s attempts to quiet a public anger over its $600 price tag for EpiPen weren’t enough to escape a congressional inquiry. The House Oversight and Government Reform Committee called for the generic ...

WASHINGTON – The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from ...